SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?


To: tom pope who wrote (198)2/3/2004 4:20:00 PM
From: tuck  Read Replies (3) | Respond to of 510
 
[reproducibility of SELDI experiments]

>>Bioinformatics. 2004 Jan 29 [Epub ahead of print]

Reproducibility of SELDI-TOF protein patterns in serum: comparing data sets from different experiments.

Baggerly KA, Morris JS, Coombes KR.

Department of Biostatistics U.T. M.D. Anderson Cancer Center 1515 Holcombe Blvd, Box 447 Houston, TX 77030-4009, USA.

MOTIVATION: There has been much interest in using patterns derived from surface-enhanced laser desorption and ionization (SELDI) protein mass spectra from serum to differentiate samples from patients both with and without disease. Such patterns have been used without identification of the underlying proteins responsible. However, there are questions as to the stability of this procedure over multiple experiments. RESULTS: We compared SELDI proteomic spectra from serum from 3 experiments by the same group (Petricoin et al., 2002) on separating ovarian cancer from normal tissue. These spectra are available on the web at clinicalproteomics.steem.com. In general, the results were not reproducible across experiments. Baseline correction prevents reproduction of the results for two of the experiments. In one experiment there is evidence of a major shift in protocol mid-experiment which could bias the results. In another, structure in the noise regions of the spectra allows us to distinguish normal from cancer, suggesting that the normals and cancers were processed differently. Sets of features found to discriminate well in one experiment do not generalize to other experiments. Finally, the mass calibration in all three experiments appears suspect. Taken together, these and other concerns suggest that much of the structure uncovered in these experiments could be due to artifacts of sample processing, not to the underlying biology of cancer. We provide some guidelines for design and analysis in experiments like these to better ensure reproducible, biologically meaningfully results. AVAILABILITY: The MATLAB and Perl code used in our analyses is available at bioinformatics.mdanderson.org.<<

>>Mol Cell Proteomics. 2004 Jan 30 [Epub ahead of print]

Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations.

Diamandis EP.

Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5.

Serum proteomic profiling, by using surfaced-enhanced laser desorbtion ionization-time-of-flight mass spectrometry (SELDI-TOF), is one of the most promising new approaches for cancer diagnostics. Exceptional sensitivities and specificities have been reported for some cancer types such as prostate, ovarian, breast and bladder cancers. These sensitivities/specificities are far superior to those obtained by using classical cancer biomarkers. In this review, I concentrate more on questions which cast doubt on the results reported and propose experiments to investigate these questions in detail before the technique is used at the clinic. It is clear that the method needs to be externally and thoroughly validated before clinical implementation is warranted.<<

To what extent this is true in competing MS techniques . . . not sure, but I'd guess it's about even.

Still, not healthy for the company.

Cheers, Tuck